WO2014012849A1 - A new crystal form of cefoperazone sodium - Google Patents

A new crystal form of cefoperazone sodium Download PDF

Info

Publication number
WO2014012849A1
WO2014012849A1 PCT/EP2013/064727 EP2013064727W WO2014012849A1 WO 2014012849 A1 WO2014012849 A1 WO 2014012849A1 EP 2013064727 W EP2013064727 W EP 2013064727W WO 2014012849 A1 WO2014012849 A1 WO 2014012849A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
sodium
cefoperazone
crystal
min
Prior art date
Application number
PCT/EP2013/064727
Other languages
French (fr)
Inventor
Chang-Long MAO
Jian-jun XU
Bo Song
Original Assignee
Dsm Sinochem Pharmaceuticals Netherlands B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201210256416 priority Critical
Priority to CN201210256416.0 priority
Application filed by Dsm Sinochem Pharmaceuticals Netherlands B.V. filed Critical Dsm Sinochem Pharmaceuticals Netherlands B.V.
Publication of WO2014012849A1 publication Critical patent/WO2014012849A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48Methylene radicals, substituted by hetero rings
    • C07D501/56Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings

Abstract

The present invention relates to a new crystal form of cefoperazone sodium and the method for making said crystal form. The new crystal form has the following characteristics: orthorhombic crystal, space group F222, unit cell dimensions a=52.15Å, b=51.87Å and c=4.95 Å.

Description

A NEW CRYSTAL FORM OF CEFOPERAZONE SODIUM

Field of the invention

The present invention relates to the field of pharmaceuticals. Especially, it is related to a new crystal form of cefoperazone sodium. The present invention also is related to a method for preparing crystalline cefoperazone sodium.

Background of the invention

Cefoperazone sodium belongs to the class of third generation cephalosporins and has many advantages including a broad antimicrobial spectrum, resistance to β-lactamases, low toxicity and strong antibiotic activity. The compound is widely applied in clinical therapy.

Cefoperazone sodium has been provided in amorphous or crystalline forms. So far, the crystalline forms include Crystal Form A and Crystal Form B (See Chinese Patent Application No. CN 1970561A (publication date May 30, 2007, entitled "A new crystal form of cefoperazone sodium and its production method"); and Xue J., Chang- qin H., Li-hong Y., Rui-ping W., Jian-wen L, et al. (201 1 ) Journal Addiction Research & Therapy, 2:1 16. doi:10.4172/2155-6105.10001 16 "Relationship between Crystal Form of Cefoperazone Sodium and Its Stability"). Crystal Form A belongs to the triclinic crystal system, and Crystal Form B belongs to the monoclinic crystal system.

The present invention provides a new crystal form of cefoperazone sodium, referred to as Crystal Form C. Crystal Form C belongs to the orthorhombic crystal system. The present invention also provides a method for making Crystal Form C of cefoperazone sodium. Detailed description of the invention

In a first aspect, the present invention provides a new crystal form of cefoperazone sodium, hereafter referred to as crystal Form C, the XRD spectrum of which is given in Figure 1 .

Crystal Form C is an orthorhombic crystal, distinguishing from the crystal forms in the prior art documents, i.e. Crystal Forms A and B. Based on the cell parameter of the crystal system, the orthorhombic crystal system has the following characteristics: a≠b≠c and all angles = 90°.

In one embodiment, the unit cell dimensions are a=52.0±0.5A, b=52.0±0.5A, c=5.0±0.5A with the proviso that a≠b≠c. In another embodiment the ratio a:b:c=(1.00±0.05):(1 .00±0.05):(0.10±0.01 ) with the proviso that a≠b≠c. In a preferred embodiment a=52.15A, b=51 .87A and c=4.95A. In a most preferred embodiment a=52.1516038A, b=51 .8713984A and C=4.9455441A. The space group is F222.

In a second aspect, the present invention provides a method for selecting good crystals of cefoperazone sodium.

The selection is based on the diffractograms, formed by X-ray powder diffraction. The term 'good crystals of cefoperazone sodium' refers to crystals having a high crystallinity and a large crystal size. For crystals with a larger size, one can read from the diffractogram a narrower peak width and also better separation of the otherwise overlapping diffraction peaks.

For peak width (full width at half maximum, FWHM), the peak at -29=7.5° (Peak no 8 in Table 1 ) is used. The term 'FWHM' refers to the degree of the angle between the two points on the diffractogram at half of the peak height, with the unit in degrees (°). Preferably, the FWHM is less than 0.3. More preferably, the FWHM is less than 0.2. Most preferably, the FWHM is less than 0.19.

For estimation of the peak separation, the two peaks at -29=13.9° (Peak no 12 in Table 1 ) and -29=14.4° (Peak no 2 in Table 1 ) are used. As an indicator, the ratio of the intensity at the minimum (lmin) between these two peaks, at approximately 29=14.1 ° (see also Figure 2), and intensity (l3) of the peak at -29=13.9° is used. The ratio of the intensity of the peak at -29=7.5° (l2) to the peak at -29=3.3° ( , ;Peak no 1 in Table 1 ), as a side indicator, is used. Preferably, the ratio of Imin/l3 is less than 90%. More preferably, the ratio of Imin/l3 is less than 80%. Most preferably, the ratio of Imm/l3 is less than 70%. Still most preferably, the ratio of Imin/l3 is less than 65%. Preferably, the ratio of l2/ is less than 40%. More preferably, the ratio of l2/li is less than 30%. Most preferably, the ratio of l2/li is less than 20%. Still most preferably, the ratio of l2/li is less than 15%.

The method comprises the following steps:

• Preparing a crystal of cefoperazone sodium;

• Placing the crystal in an X-ray powder diffractometer to record a diffractogram;

• With the FWHM, Imin/l3 and l2/li, determining the quality grade of the crystal The three parameters, namely, the FWHM, Imin/l3 and l2/ can be changed independently. In other words, if a crystal has a small FWHM and a relatively high l2/li, it may still be regarded as a good crystal.

In a third aspect, the present invention provides a method of making a crystal form of cefoperazone sodium from cefoperazone acid. Thus, the third aspect of the present invention provides a method for the preparation of Crystal Form C of cefoperazone sodium comprising the steps of:

(a) mixing cefoperazone acid with an organic solvent and adding a sodium source;

(b) adding an anti-solvent to the mixture obtained in step (a) followed by isolating the solid material from the mixture thus obtained.

The method comprises two phases: reaction (salt-forming) and crystallization (anti-solvent crystallization).

The term 'reaction' refers to transferring the raw material cefoperazone acid into cefoperazone sodium with a salt-forming agent. The term 'crystallization' refers to forming a crystal with a solvent and an anti-solvent.

In the first phase of the method of the third aspect, cefoperazone acid is suspended in an organic solvent, preferably a ketone, more preferably acetone or a mixture of acetone and water and into the suspension a sodium source is added in portions or drop wise. A suitable sodium source is sodium bicarbonate which may be added as solid or as a solution of sodium bicarbonate in water. The temperature is controlled within the range of 0-50°C, preferably within the range of 15-23°C. After the addition of the solution of sodium bicarbonate in water, stirring is continued for a certain time. The pH is adjusted in the range of 5.5 to 7.0, preferably within the range of 6.5 to 6.6, through the addition of the solution of sodium bicarbonate in water. The cefoperazone acid, also referred to as cefoperazone free acid may be obtained from a commercial source. Alternatively, cefoperazone acid may be obtained directly from a synthetic process leading to cefoperazone acid. If so, it may exist in a reaction liquid together with other substances, such as impurities. Sodium bicarbonate functions as a salt-forming agent. Other salt-forming agents can be used, such as sodium acetate, sodium carbonate, sodium ethylhexanoate, sodium hydroxide or sodium isooctanoate. The salt-forming agents may be formulated into a solution with water and/or acetone. Preferably, the salt-forming agent is formulated into an aqueous solution. For example, sodium bicarbonate may be added as a solution in water, at a concentration of 0.08 g/ml (8% (w/v)), or 0.04 g/ml (4% (w/v)).

In the second phase of the method of the third aspect, the temperature is brought to 20-25°C. Subsequently an anti-solvent is added, such as acetone or isopropanol or, preferably, a mixture of acetone and isopropanol. Alternatively, a mixture of acetone and ethanol is added. Or, only acetone may be added. Other suitable anti-solvents are a mixture of acetone and acetonitrile, a mixture of acetone and isopropyl acetate, a mixture of acetone and 1 ,2-dichloroethane, and the like. The term 'anti-solvent' refers to the substance(s) that is added to initiate the formation of crystal. The anti-solvent may be added in portions. For example, if acetone is used, the acetone may be added in three portions, a first portion, a second portion and a third portion.

The temperature may be changed, with several platforms. For example, the temperature at the beginning of crystallization may be a temperature of 20 to 25°C, then the temperature may be lowered to 18°C, and then in the end, the temperature may be further lowered to a range of 10-15°C.

In a fourth aspect, the present invention provides a pharmaceutical composition comprising Crystal Form C of cefoperazone sodium.

Crystal Form C of cefoperazone sodium can be used to treat the diseases that are treated with cefoperazone sodium or cefoperazone acid, preferably in a suitable formulation. Any composition comprising Crystal Form C is within the scope of the present invention.

In a fifth aspect, the present invention provides the use of Crystal Form C of cefoperazone sodium in the preparation of an anti-infective medicament.

Legend to the Figures

Figure 1 is the XRD spectrum of Crystal Form C of cefoperazone sodium. X-axis: 2-theta value (deg). Y-axis: intensity (cps). The following 25 strongest peaks are given below in Table 1 .

Table 1 : Peak position (in 2-theta and d spacing) and relative peak intensity for the 25 strongest peaks used for the indexing

Peak no 2-Theta (deg) d Spacing (A) l/lo (%)

1 3.299 26.76 100

2 14.350 6.167 86.69

3 19.838 4.472 83.83

4 20.422 4.345 63.06

5 17.992 4.926 59.93

6 21 .521 4.126 56.93

7 18.624 4.760 49.83

8 7.505 1 1 .77 41 .26

9 4.712 18.74 36.16

10 25.071 3.549 31 .26

1 1 26.455 3.366 27.46

12 13.941 6.347 30.49

13 10.107 8.745 27.79

14 26.010 3.423 23.82

15 19.238 4.610 20.24

16 9.527 9.275 18.36

17 6.710 13.16 17.67

18 24.1 13 3.688 17.64

19 22.080 4.023 17.49

20 20.666 4.295 16.79

21 23.628 3.762 15.56

22 10.663 8.290 14.06

23 27.339 3.260 1 1 .96

24 15.137 5.849 10.35

25 16.931 5.233 8.1 16 Figure 2 is the determination of lmin (position marked with arrow) from the XRD spectrum of Crystal Form C of cefoperazone sodium. X-axis: 2-theta value (deg). Y-axis: intensity in arbitrary units (a.u.).

EXAMPLES

The present invention is further illustrated below with reference to the concrete examples. It is to be understood that these examples are to describe the present invention, not to limit the scope of the present invention. It is also to be understood that those skills in the art may make various modifications or alterations after reading the content taught by the present invention. These equivalents also fall within the scope limited by the claims of this application.

Example 1

To a suspension of 10.0 g of cefoperazone free acid in 40 ml acetone, stirred at 15-20°C, 15.4 ml of 8% sodium bicarbonate in water was added drop wise in 30 min, to a final pH of 6.5-6.6. The resulting solution was kept stirring for 10 min and subsequently transferred into a crystallization reactor after which 35 ml of a mixture acetone:isopropanol (2:1 ) was added in 10 min with vigorous stirring (stirring speed at about 250 rpm). The temperature was kept at 20-25°C. The mixture was then stirred for 30 min at 80 rpm. Another portion of 75 ml acetone:isopropanol (2:1 ) mixture was added at the same temperature and the stirring speed was adapted to 100 rpm. After stirring for 40-50 min, 80 ml acetone:isopropanol (2:1 ) mixture was added in 15 min and the temperature was adjusted to 10-15 °C, after which stirring was continued at 80 rpm for approximately 30 min. The slurry was filtered and washed twice with 50 ml acetone each time. The resulting white solid was dried for 20 h at room temperature. The dried white solid was used as crystal seed for Examples 2-6.

Example 2

To a suspension of 10.0 g of cefoperazone free acid in 40 ml acetone, stirred at 15-20°C, 15.4 ml of 8% sodium bicarbonate in water was added drop wise in 30 min, to a final pH of 6.5-6.6. The resulting solution was kept stirring for 10 min and subsequently transferred into a crystallization reactor after which 35 ml of a mixture acetone:isopropanol (2:1 ) was added in 10 min with vigorous stirring (stirring speed at about 250 rpm). The temperature was kept at 20-25°C. Seed crystals from Example 1 were added and the mixture was stirred for 30 min at 80 rpm. Another portion of 75 ml acetone:isopropanol (2:1 ) was added at the same temperature and the stirring speed was adapted to 100 rpm. After stirring for 40-50 min, 80 ml acetone:isopropanol (2:1 ) mixture was added in 15 min after which the temperature was adjusted to 10-15°C and stirring was continued for approximately 30 min at 80 rpm. The resulting slurry was filtered and washed twice with 50 ml acetone each time. The resulting white solid was dried in vacuum at 40 °C. The isolated yield was approximately 9.3 g (89.9%).

Example 3

This crystallization experiment was performed as described above for Example 2. The anti-solvent used was acetone:isopropanol (10:1 ). The isolated yield was approximately 10.1 g (97.6%).

Example 4

The crystallization experiment was performed as described above for Example 2. The anti-solvent used was acetone:ethanol (2:1 ). The isolated yield was approximately 9.0 g (87.0%).

Example 5

The crystallization experiment was performed as described above for Example 2. The anti-solvent used was acetone:ethanol (10:1 ). The isolated yield was approximately 9.8 g (94.8%).

Example 6

To a suspension of 10.0 g of cefoperazone free acid in 40 ml acetone and 5 ml water, stirred at 15-20°C, 15.4 ml of 8% sodium bicarbonate in water was added drop wise in 30 min, to a final pH of 6.5-6.6. The resulting solution was kept stirring for 10 min and subsequently transferred into a crystallization reactor after which 50 ml of acetone was added in 10 min with vigorous stirring (stirring speed was approximately 120 rpm). The temperature was kept at 20-25°C. Seed crystals from Example 1 were added and the mixture was stirred for 30 min at 80 rpm. Another portion of 100 ml acetone was added at the same temperature and the stirring speed was kept at 80 rpm. After stirring for 30 min, 100 ml acetone was added in 15 min and the temperature was adjusted to 10-15°C, after which stirring was continued for approximately 30 min at 80 rpm. The resulting slurry was filtered and washed twice with 50 mL acetone each time. The resulting solid was dried in vacuum. The isolated yield was approximately 10.15 g (98.1 %).

Example 7

For the crystals obtained in Examples 2-6, the X-ray powder diffractograms were recorded on an X-ray powder diffractometer from BRUKER, D8 ADVANCE, which uses copper Ka radiation and has a VANTEC array detector with divergence slit angle set at

0.3°. The scanning angle 2Θ ranged from 2° to 60°, with step (in 2Θ) around 0.007°, and the count time 1 s/step. The sample rotated at 15 rpm during the measurement. The measurements were carried out at room temperature and ambient humidity.

For the crystal prepared in Example 2, the FWHM is 0.188°, the l2/ is 29.7%, and the

Imin l3 is 63.7%. The quality of the crystal was marked as Grade 1 .

For the crystal prepared in Example 4, the FWHM is 0.182°, the l2/ is 28.4%, and the

Imin l3 is 58.9%. The quality of the crystal was marked as Grade 1 .

Example 8

The indexing of the X-ray powder data was carried out using program TOPAS 4-2 from Bruker. The crystal prepared in Example 2 was tested by HPLC and confirmed the purity of >99%, in respect of organic impurities. The X-ray powder diffraction data of this crystal was used for the indexing. The data was recorded on the same diffractometer as for Example 7, but using a position sensitive detector (PSD) (i.e. scintillation counter). The count time was 20s/step. The data was additionally corrected in sample displacement error by an extra measurement using silicon powder (NIST SRM 640d) as an external standard. The thus collected data, which were used as input for indexing the crystal structure, are summarized in Table 1 (see Legend to Figure 1 ). The conclusion from the above indexing was that the crystal belongs to an orthorhombic crystal system with space group F222, unit cell dimensions are a=52.1516038A, b=51.8713984A and C=4.9455441A.

Claims

1 . Crystal Form C of cefoperazone sodium, characterized in that it is an orthorhombic crystal.
2. The Crystal Form C according to claim 1 , wherein the unit cell parameters are a=52.0±0.5A, b=52.0±0.5A, c=5.0±0.5A with the proviso that a≠b≠c.
3. The Crystal Form C according to claim 2, wherein the unit cell parameters are a=52.15A, b=51 .87A and c=4.95A.
4. The Crystal Form C according to claim 3, wherein the unit cell parameters are a=52.1516038A, b=51 .8713984A and c=4.9455441 A and the space group is F222.
5. The Crystal Form C according to claim 1 , wherein the unit cell parameters are a:b:c=(1 .00±0.05):(1 .00±0.05):(0.10±0.01 ) with the proviso that a≠b≠c.
6. Method for the preparation of Crystal Form C of cefoperazone sodium comprising the steps of:
(a) mixing cefoperazone acid with an organic solvent and adding a sodium source;
(b) adding an anti-solvent to the mixture obtained in step (a) followed by isolating the solid material from the mixture thus obtained.
7. Method according to claim 6 wherein said organic solvent is a ketone or a mixture of a ketone and water and said anti-solvent comprises acetone.
8. Method according to claim 7 wherein said sodium source is sodium bicarbonate.
9. Use of the Crystal Form C according to any one of claims 1 to 5 in the preparation of an anti-infective medicament.
PCT/EP2013/064727 2012-07-17 2013-07-11 A new crystal form of cefoperazone sodium WO2014012849A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201210256416 2012-07-17
CN201210256416.0 2012-07-17

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201380037665 CN104470933A (en) 2012-07-17 2013-07-11 A new crystal form of cefoperazone sodium

Publications (1)

Publication Number Publication Date
WO2014012849A1 true WO2014012849A1 (en) 2014-01-23

Family

ID=48782346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/064727 WO2014012849A1 (en) 2012-07-17 2013-07-11 A new crystal form of cefoperazone sodium

Country Status (2)

Country Link
CN (1) CN104470933A (en)
WO (1) WO2014012849A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327099A (en) * 2014-09-29 2015-02-04 联合康兴(北京)医药科技有限公司 Cefoperazone sodium compound entity, composition and application

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432273A (en) * 2016-09-07 2017-02-22 陕西顿斯制药有限公司 Cefoperazone sodium compound prepared by using fluid mechanics principle and preparation comprising cefoperazone sodium compound
CN106432277A (en) * 2016-09-21 2017-02-22 陕西顿斯制药有限公司 Cefoperazone sodium compound and sulbactam sodium compound prepared with strong-field coupling crystallization technology as well as prepared composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101170A1 (en) * 1982-07-19 1984-02-22 Pfizer Inc. Process for the manufacture of sodium cefoperazone
US4456753A (en) * 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
WO2001079210A2 (en) * 2000-04-14 2001-10-25 Antibioticos S.P.A. A process for the preparation of highly crystalline sodium cefoperazone
CN1970561A (en) 2005-11-22 2007-05-30 上海新先锋药业有限公司 Cefoperazone sodium novel crystal form and its preparation method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863907B (en) * 2010-07-07 2012-05-23 福建省福抗药业股份有限公司 Method for crystallizing cefoperazone sodium
CN102372729B (en) * 2011-12-14 2014-09-24 哈药集团制药总厂 Novel method for synthesizing cefoperazone sodium compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101170A1 (en) * 1982-07-19 1984-02-22 Pfizer Inc. Process for the manufacture of sodium cefoperazone
US4456753A (en) * 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
WO2001079210A2 (en) * 2000-04-14 2001-10-25 Antibioticos S.P.A. A process for the preparation of highly crystalline sodium cefoperazone
CN1970561A (en) 2005-11-22 2007-05-30 上海新先锋药业有限公司 Cefoperazone sodium novel crystal form and its preparation method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. XUE ET AL.: "Relationship between crystal form of cefoperazone sodium and its stability", J. ADDICT. RES. TER., vol. 2, no. 4, 2011, pages 1 - 6, XP002713257 *
XUE J.; CHANG- QIN H.; LI-HONG Y.; RUI-PING W.; JIAN-WEN L. ET AL., JOURNAL ADDICTION RESEARCH & THERAPY, vol. 2, 2011, pages 116

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327099A (en) * 2014-09-29 2015-02-04 联合康兴(北京)医药科技有限公司 Cefoperazone sodium compound entity, composition and application

Also Published As

Publication number Publication date
CN104470933A (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CN101260114B (en) Polymorphous forms of rifaximin, preparation and application thereof used in pharmaceutical preparation
AT392472B (en) A method for preparing a stable crystalline trihydrate of the di- or 7beta- ((Z) -2- (2-aminothiazol-4-yl) -4-carboxybut-2-enoylamino) -3-cephem-4-carboxylic acid
EP1956014B1 (en) Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
JP4233115B2 (en) Preparation of the magnesium salt of a substituted sulfinyl heterocyclic compound
ES2393972T3 (en) Amorphous cephalosporin compositions, crystallographically stable and method of preparation thereof
US8372995B2 (en) Crystalline solid forms of tigecycline and methods of preparing same
CN101970425B (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
JP4573154B2 (en) The novel crystalline form of cefdinir
CA2554888A1 (en) Rosiglitazone phosphate and polymorphic forms
US7642353B2 (en) Process of making crystalline aripiprazole
Eddleston et al. Screening for polymorphs of cocrystals: a case study
PT757991E (en) Crystalline form of cefuroxima axetil biodisponivel
JP5748954B2 (en) Crystal and manufacturing method thereof thiazolidinediones
EP2966072A2 (en) Crystalline forms of nilotinib hydrobromide, succinate, glutamate, acetate, l-malate and maleate
WO2011054917A1 (en) Process for the production of polymorph form i of agomelatine
JP3726291B2 (en) Benzoxazine compound having a stable crystal structure and their preparation
SK4232001A3 (en) New crystal modification iii of torasemide
US20070244315A1 (en) Process for the preparation of cefdinir
WO2013044816A1 (en) Crystalline forms of azilsartan and preparation and uses thereof
WO2007010555A2 (en) Novel crystalline forms of moxifloxacin hydrochloride and process for preparation thereof
US20110086871A1 (en) Rifaximin compositions and method of use
US7674898B2 (en) Anhydrous crystal of β-lactam compound and method for preparation thereof
JP2011503185A (en) Polymorphic forms and their preparation process of aliskiren hemifumarate
US20090124811A1 (en) Method for resolving omeprazole salts
EP2994468B1 (en) Crystalline hydrates of 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13735307

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13735307

Country of ref document: EP

Kind code of ref document: A1